On the public citation graph
Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease
0 signed · 546 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1001/jama.2020.12134openalex-snapshot
Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders
inferredcites →https://doi.org/10.1001/jamaneurol.2021.2293openalex-snapshot
Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes
inferredcites →https://doi.org/10.1001/jamaneurol.2021.3180openalex-snapshot
Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease
inferredcites →https://doi.org/10.1002/acn3.51553openalex-snapshot
Phospho‐specific plasma p‐tau181 assay detects clinical as well as asymptomatic Alzheimer's disease
inferredcites →https://doi.org/10.1002/alz.12395openalex-snapshot
Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p‐tau
inferredcites →https://doi.org/10.1002/ana.26308openalex-snapshot
Plasma p‐tau231, p‐tau181, PET Biomarkers, and Cognitive Change in Older Adults
inferredcites →https://doi.org/10.1002/dad2.12204openalex-snapshot
Development and validation of a high‐sensitivity assay for measuring p217+tau in plasma
inferredcites →https://doi.org/10.1002/dad2.12307openalex-snapshot
Plasma p217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum
inferredcites →https://doi.org/10.1007/s00401-021-02275-6openalex-snapshot
Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology
inferredcites →https://doi.org/10.1007/s00401-022-02408-5openalex-snapshot
Plasma biomarkers for Alzheimer’s Disease in relation to neuropathology and cognitive change
inferredcites →https://doi.org/10.1016/j.clinms.2019.07.002openalex-snapshot
Use of the tau protein-to-peptide ratio in CSF to improve diagnostic classification of Alzheimer’s disease
inferredcites →https://doi.org/10.1016/j.jalz.2011.03.005openalex-snapshot
The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
inferredcites →https://doi.org/10.1016/j.jalz.2018.02.013openalex-snapshot
Plasma phospho‐tau181 increases with Alzheimer's disease clinical severity and is associated with tau‐ and amyloid‐positron emission tomography
inferredcites →https://doi.org/10.1016/j.tips.2015.03.002openalex-snapshot
Amyloid biomarkers in Alzheimer's disease
inferredcites →https://doi.org/10.1016/s1474-4422(20)30071-5openalex-snapshot
Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts
inferredcites →https://doi.org/10.1016/s1474-4422(21)00214-3openalex-snapshot
Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study
inferredcites →https://doi.org/10.1016/s1474-4422(22)00168-5openalex-snapshot
Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials
inferredcites →https://doi.org/10.1038/nrneurol.2010.4openalex-snapshot
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
inferredcites →https://doi.org/10.1038/s41467-020-15436-0openalex-snapshot
Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease
inferredcites →https://doi.org/10.1038/s41591-020-0755-1openalex-snapshot
Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia
inferredcites →https://doi.org/10.1038/s41591-020-0762-2openalex-snapshot
Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration
inferredcites →https://doi.org/10.1038/s41591-020-0781-zopenalex-snapshot
A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease
inferredcites →https://doi.org/10.1038/s41591-021-01348-zopenalex-snapshot
Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures
inferredcites →https://doi.org/10.1038/s41591-021-01382-xopenalex-snapshot
Biomarkers for neurodegenerative diseases
inferredcites →https://doi.org/10.1084/jem.20200861openalex-snapshot
Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease
inferredcites →https://doi.org/10.1111/j.1365-2796.2004.01388.xopenalex-snapshot
Mild cognitive impairment as a diagnostic entity
inferredcites →https://doi.org/10.1126/science.abi5208openalex-snapshot
Phenotyping Alzheimer's disease with blood tests
inferredcites →https://doi.org/10.1186/1471-2105-12-77openalex-snapshot
pROC: an open-source package for R and S+ to analyze and compare ROC curves
inferredcites →https://doi.org/10.1186/s13195-020-00596-4openalex-snapshot
Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer’s disease and PET amyloid-positive patient identification
inferredcites →https://doi.org/10.1186/s13195-021-00804-9openalex-snapshot
Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment
inferredcites →https://doi.org/10.1186/s13195-021-00939-9openalex-snapshot
Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231
inferredcites →https://doi.org/10.1186/s13195-022-01005-8openalex-snapshot
Diagnostic and prognostic performance to detect Alzheimer’s disease and clinical progression of a novel assay for plasma p-tau217
inferredcites →https://doi.org/10.15252/emmm.202114408openalex-snapshot
Blood‐based biomarkers for Alzheimer's disease
inferredcites →https://doi.org/10.3233/jad-2010-100207openalex-snapshot
Evaluation of CSF Biomarkers as Predictors of Alzheimer's Disease: A Clinical Follow-Up Study of 4.7 Years
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4771390openalex-extracted
Accurate Detection and Staging of Alzheimer's Disease by Plasma Ptau217 on a High Throughput Immunoassay Platform
inferred← citeshttps://doi.org/10.1001/jama.2024.12814openalex-snapshot
Are Blood Tests for Alzheimer Disease Ready for Prime Time?
inferred← citeshttps://doi.org/10.1001/jama.2024.13855openalex-snapshot
Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2026.1295openalex-snapshot
Plasma Phosphorylated Tau 217 and Incident Mild Cognitive Impairment and Dementia in Older Women
inferred← citeshttps://doi.org/10.1001/jamaneurol.2023.0050openalex-snapshot
Alzheimer Disease Blood Biomarkers in Patients With Out-of-Hospital Cardiac Arrest
inferred← citeshttps://doi.org/10.1001/jamaneurol.2023.0199openalex-snapshot
Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratios
inferred← citeshttps://doi.org/10.1001/jamaneurol.2023.1323openalex-snapshot
Clinical Utility of Tau Positron Emission Tomography in the Diagnostic Workup of Patients With Cognitive Symptoms
inferred← citeshttps://doi.org/10.1001/jamaneurol.2023.4596openalex-snapshot
Plasma Biomarker Strategy for Selecting Patients With Alzheimer Disease for Antiamyloid Immunotherapies
inferred← citeshttps://doi.org/10.1001/jamaneurol.2023.5319openalex-snapshot
Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology
inferred← citeshttps://doi.org/10.1001/jamaneurol.2024.2619openalex-snapshot
Plasma Phosphorylated Tau 217 and Aβ42/40 to Predict Early Brain Aβ Accumulation in People Without Cognitive Impairment
inferred← citeshttps://doi.org/10.1001/jamaneurol.2024.2801openalex-snapshot
Blood-Based Biomarkers for Alzheimer Disease—Ready for Primary Care?
inferred← citeshttps://doi.org/10.1001/jamaneurol.2024.5017openalex-snapshot
Detection of Alzheimer Neuropathology in Alzheimer and Non-Alzheimer Clinical Syndromes With Blood-Based Biomarkers
inferred← citeshttps://doi.org/10.1001/jamaneurol.2025.2972openalex-snapshot
Evolving Role of Plasma Phosphorylated Tau 217 in Alzheimer Disease—Time for Tau
inferred← citeshttps://doi.org/10.1001/jamaneurol.2025.3217openalex-snapshot
Plasma Phosphorylated Tau 217 to Identify Preclinical Alzheimer Disease
inferred← citeshttps://doi.org/10.1001/jamaneurol.2026.3497openalex-snapshot
Earlier Disclosure of Blood-Based Biomarkers, Diagnostic Certainty, and Clinical Management
inferred← citeshttps://doi.org/10.1002/2211-5463.13667openalex-snapshot
Novel aspects of the phosphorylation and structure of pathological tau: implications for tauopathy biomarkers
inferred← citeshttps://doi.org/10.1002/9783527844678.ch7openalex-snapshot
Biomarkers in CNS Drug Discovery, Drug Development, and Clinical Implementation
inferred← citeshttps://doi.org/10.1002/acn3.70387openalex-snapshot
Predictive Ability of Plasma p‐tau217 for β‐Amyloid Status: A Prospective Multicenter Study
inferred← citeshttps://doi.org/10.1002/alz.075367openalex-snapshot
Novel CSF tau biomarkers can be used for disease staging of sporadic Alzheimer’s
inferred← citeshttps://doi.org/10.1002/alz.12997openalex-snapshot
Differences between ante mortem Alzheimer's disease biomarkers in predicting neuropathology at autopsy
inferred← citeshttps://doi.org/10.1002/alz.13022openalex-snapshot
Prospective evaluation of plasma phosphorylated tau in a real‐life memory clinic in Thailand
inferred← citeshttps://doi.org/10.1002/alz.13026openalex-snapshot
Equivalence of plasma p‐tau217 with cerebrospinal fluid in the diagnosis of Alzheimer's disease
inferred← citeshttps://doi.org/10.1002/alz.13116openalex-snapshot
Translating blood biomarkers into clinical practice for Alzheimer's disease: Challenges and perspectives
inferred← citeshttps://doi.org/10.1002/alz.13455openalex-snapshot
The potential clinical value of plasma biomarkers in Alzheimer's disease
inferred← citeshttps://doi.org/10.1002/alz.13456openalex-snapshot
Plasma Alzheimer's biomarkers and brain amyloid in Hispanic and non‐Hispanic older adults
inferred← citeshttps://doi.org/10.1002/alz.13510openalex-snapshot
Comparative methods for quantifying plasma biomarkers in Alzheimer's disease: Implications for the next frontier in cerebral amyloid angiopathy diagnostics
inferred← citeshttps://doi.org/10.1002/alz.13518openalex-snapshot
Biological variation estimates of Alzheimer's disease plasma biomarkers in healthy individuals
inferred← citeshttps://doi.org/10.1002/alz.13528openalex-snapshot
Plasma pTau‐217 and N‐terminal tau (NTA) enhance sensitivity to identify tau PET positivity in amyloid‐β positive individuals
inferred← citeshttps://doi.org/10.1002/alz.13539openalex-snapshot
Modeling the temporal evolution of plasma p‐tau in relation to amyloid beta and tau PET
inferred← citeshttps://doi.org/10.1002/alz.13557openalex-snapshot
Uncovering elevated tau TPP motif phosphorylation in the brain of Alzheimer's disease patients
inferred← citeshttps://doi.org/10.1002/alz.13651openalex-snapshot
Comparison of plasma biomarkers and amyloid PET for predicting memory decline in cognitively unimpaired individuals
inferred← citeshttps://doi.org/10.1002/alz.13686openalex-snapshot
Scalable plasma and digital cognitive markers for diagnosis and prognosis of Alzheimer's disease and related dementias
inferred← citeshttps://doi.org/10.1002/alz.13687openalex-snapshot
Fully automated measurement of plasma Aβ42/40 and p‐tau181: Analytical robustness and concordance with cerebrospinal fluid profile along the Alzheimer's disease continuum in two independent cohorts
inferred← citeshttps://doi.org/10.1002/alz.13762openalex-snapshot
Blood tests for Alzheimer's disease: The impact of disease prevalence on test performance
inferred← citeshttps://doi.org/10.1002/alz.13764openalex-snapshot
Clinical validation of the PrecivityAD2 blood test: A mass spectrometry‐based test with algorithm combining %p‐tau217 and Aβ42/40 ratio to identify presence of brain amyloid
inferred← citeshttps://doi.org/10.1002/alz.13859openalex-snapshot
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
inferred← citeshttps://doi.org/10.1002/alz.14088openalex-snapshot
Development of thresholds and a visualization tool for use of a blood test in routine clinical dementia practice
inferred← citeshttps://doi.org/10.1002/alz.14138openalex-snapshot
The Bayesian approach for real‐world implementation of plasma p‐tau217 in tertiary care memory clinics in Thailand
inferred← citeshttps://doi.org/10.1002/alz.14201openalex-snapshot
Clinical use of biomarkers in the era of Alzheimer's disease treatments
inferred← citeshttps://doi.org/10.1002/alz.14202openalex-snapshot
Clinical criteria for limbic‐predominant age‐related TDP‐43 encephalopathy
inferred← citeshttps://doi.org/10.1002/alz.14315openalex-snapshot
Head‐to‐head comparison of leading blood tests for Alzheimer's disease pathology
inferred← citeshttps://doi.org/10.1002/alz.14338openalex-snapshot
Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup
inferred← citeshttps://doi.org/10.1002/alz.14367openalex-snapshot
Generalizability of tau and amyloid plasma biomarkers in Alzheimer's disease cohorts of diverse genetic ancestries
inferred← citeshttps://doi.org/10.1002/alz.14397openalex-snapshot
Plasma p‐tau immunoassays in clinical research for Alzheimer's disease
inferred← citeshttps://doi.org/10.1002/alz.14398openalex-snapshot
Predicting conversion in cognitively normal and mild cognitive impairment individuals with machine learning: Is the CSF status still relevant?
inferred← citeshttps://doi.org/10.1002/alz.14413openalex-snapshot
Benchmarking of a multi‐biomarker low‐volume panel for Alzheimer's disease and related dementia research
inferred← citeshttps://doi.org/10.1002/alz.14458openalex-snapshot
Diagnostic accuracy of phosphorylated tau217 in detecting Alzheimer's disease pathology among cognitively impaired and unimpaired: A systematic review and meta‐analysis
inferred← citeshttps://doi.org/10.1002/alz.14495openalex-snapshot
Association of rapid eye movement sleep latency with multimodal biomarkers of Alzheimer's disease
inferred← citeshttps://doi.org/10.1002/alz.14502openalex-snapshot
Clinical utility of plasma p‐tau217 in identifying abnormal brain amyloid burden in an Asian cohort with high prevalence of concomitant cerebrovascular disease
inferred← citeshttps://doi.org/10.1002/alz.14508openalex-snapshot
The Alzheimer's Association Global Biomarker Standardization Consortium (GBSC) plasma phospho‐tau Round Robin study
inferred← citeshttps://doi.org/10.1002/alz.14526openalex-snapshot
Differential roles of Alzheimer's disease plasma biomarkers in stepwise biomarker‐guided diagnostics
inferred← citeshttps://doi.org/10.1002/alz.14528openalex-snapshot
Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease
inferred← citeshttps://doi.org/10.1002/alz.14536openalex-snapshot
Plasma p‐tau217 and p‐tau217/Aβ1‐42 are effective biomarkers for identifying CSF‐ and PET imaging‐diagnosed Alzheimer's disease: Insights for research and clinical practice
inferred← citeshttps://doi.org/10.1002/alz.14565openalex-snapshot
Cross‐cultural validation of plasma p‐tau217 and p‐tau181 as precision biomarkers for amyloid PET positivity: An East Asian study in Taiwan and Korea
inferred← citeshttps://doi.org/10.1002/alz.14570openalex-snapshot
Accuracy of plasma biomarkers to detect Alzheimer's disease proteinopathy prior to dementia
inferred← citeshttps://doi.org/10.1002/alz.14573openalex-snapshot
Diagnostic performance of plasma Aβ42/40 ratio, p‐tau181, GFAP, and NfL along the continuum of Alzheimer's disease and non‐AD dementias: An international multi‐center study
inferred← citeshttps://doi.org/10.1002/alz.14594openalex-snapshot
White matter injury, plasma Alzheimer's disease, and neurodegenerative biomarkers on cognitive decline in community‐dwelling older adults: A 10‐year longitudinal study
inferred← citeshttps://doi.org/10.1002/alz.14600openalex-snapshot
Machine learning prediction of tau‐PET in Alzheimer's disease using plasma, MRI, and clinical data
inferred← citeshttps://doi.org/10.1002/alz.14609openalex-snapshot
A head‐to‐head comparison of plasma biomarkers to detect Alzheimer's disease in a memory clinic
inferred← citeshttps://doi.org/10.1002/alz.14629openalex-snapshot
Plasma Alzheimer's disease biomarker relationships with incident abnormal amyloid PET
inferred← citeshttps://doi.org/10.1002/alz.70113openalex-snapshot
Cut‐points and gray zones: The challenges of integrating Alzheimer's disease plasma biomarkers into clinical practice
inferred← citeshttps://doi.org/10.1002/alz.70173openalex-snapshot
Differences in Alzheimer's disease blood biomarker stability: Implications for the use of tau/amyloid ratios
inferred← citeshttps://doi.org/10.1002/alz.70201openalex-snapshot
Global multi‐specialty clinician perspectives on the implementation of Alzheimer's disease blood biomarkers
inferred← citeshttps://doi.org/10.1002/alz.70208openalex-snapshot
A comparison of p‐tau assays for the specificity to detect tau changes in Alzheimer's disease
inferred← citeshttps://doi.org/10.1002/alz.70315openalex-snapshot
Influence of ethnicity on the diagnostic accuracy of plasma p‐tau217 for the identification of Alzheimer's disease: A consecutive mixed memory clinic cohort study
inferred← citeshttps://doi.org/10.1002/alz.70421openalex-snapshot
Plasma p‐tau231 in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: A cross‐sectional and longitudinal cohort study
inferred← citeshttps://doi.org/10.1002/alz.70426openalex-snapshot
Evaluation of plasma p‐tau217 for detecting amyloid pathology in a heterogeneous community‐based cohort
inferred← citeshttps://doi.org/10.1002/alz.70469openalex-snapshot
Comparison of plasma p‐tau217/Aβ42, p‐tau217, and Aβ42/Aβ40 biomarkers by race to detect Alzheimer's disease
inferred← citeshttps://doi.org/10.1002/alz.70535openalex-snapshot
Alzheimer's Association Clinical Practice Guideline on the use of blood‐based biomarkers in the diagnostic workup of suspected Alzheimer's disease within specialized care settings
inferred← citeshttps://doi.org/10.1002/alz.70536openalex-snapshot
Modernizing diagnosis of Alzheimer's disease: A review of global trends and Asia‐specific perspectives
inferred← citeshttps://doi.org/10.1002/alz.70562openalex-snapshot
Plasma tau biomarkers are distinctly associated with tau tangles and decreased with Lewy body pathology
inferred← citeshttps://doi.org/10.1002/alz.70625openalex-snapshot
Association of plasma Alzheimer's disease biomarkers with cognitive decline in cognitively unimpaired individuals
inferred← citeshttps://doi.org/10.1002/alz.70641openalex-snapshot
Employment, volunteering, and health‐related resource use in pre‐symptomatic AD: Results from the Anti‐Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) study
inferred← citeshttps://doi.org/10.1002/alz.70745openalex-snapshot
Retinal microvascular alterations in Alzheimer's disease: Linking blood plasma biomarkers and cerebral small vessel pathology
inferred← citeshttps://doi.org/10.1002/alz.70750openalex-snapshot
Lecanemab treatment for Alzheimer's Disease of varying severities and associated plasma biomarkers monitoring: A multi‐center real‐world study in China
inferred← citeshttps://doi.org/10.1002/alz.70763openalex-snapshot
Complementary utility of plasma biomarkers and Aβ‐PET for diagnosis, risk‐stratification, and treatment monitoring in Alzheimer's disease
inferred← citeshttps://doi.org/10.1002/alz.70765openalex-snapshot
Body mass index and blood volume influence plasma biomarkers and positron emission tomography classification in preclinical Alzheimer's disease
inferred← citeshttps://doi.org/10.1002/alz.70783openalex-snapshot
A systematic comparison of ATN biomarkers for monitoring longitudinal cognitive changes in Alzheimer's disease
inferred← citeshttps://doi.org/10.1002/alz.70828openalex-snapshot
Blood‐based biomarkers for detecting Alzheimer's disease pathology in cognitively impaired individuals within specialized care settings: A systematic review and meta‐analysis
inferred← citeshttps://doi.org/10.1002/alz.70881openalex-snapshot
Combining CSF MTBR‐tau243 and plasma pTau217 ratio enhances the prediction of continuous regional tau PET burden in early Alzheimer's disease
inferred← citeshttps://doi.org/10.1002/alz.70891openalex-snapshot
Blood‐based Alzheimer's disease biomarkers in a behavioral neurology clinic: Real‐world implementation, clinical utility, and diagnostic performance
inferred← citeshttps://doi.org/10.1002/alz.70916openalex-snapshot
Cross‐cohort validation and cutpoint estimation of the Janssen plasma p‐tau217+ assay in predominantly cognitively normal community studies
inferred← citeshttps://doi.org/10.1002/alz.70937openalex-snapshot
Polygenic scores of Core 1 Alzheimer's disease biomarkers predict early cognitive and pathological change
inferred← citeshttps://doi.org/10.1002/alz.71000openalex-snapshot
Apolipoprotein E ε4 homozygosity exacerbates retinal and cerebral microvascular dysfunction in Alzheimer's disease: A mediation analysis of vascular contributions to cognitive decline
inferred← citeshttps://doi.org/10.1002/alz.71048openalex-snapshot
APOE ɛ4 carriership determines a faster plasma p‐tau217 progression in Aβ‐positive individuals
inferred← citeshttps://doi.org/10.1002/alz.71145openalex-snapshot
Plasma biomarker progression across the Alzheimer's disease amyloid beta and tau positron emission tomography trajectories
inferred← citeshttps://doi.org/10.1002/alz.71199openalex-snapshot
Plasma p‐tau217 predicts PET‐based pathological staging for precision Alzheimer disease assessment
inferred← citeshttps://doi.org/10.1002/alz.71338openalex-snapshot
The association between APOE 𝜀4 carrierships and the detection of amyloid positivity using an Alzheimer's disease proteomic blood test in asymptomatic Down syndrome
inferred← citeshttps://doi.org/10.1002/alz.71532openalex-snapshot
Age‐related increase in plasma p‐tau217 in amyloid‐beta–negative cognitively unimpaired individuals affects diagnostic interpretation
inferred← citeshttps://doi.org/10.1002/alz.71723openalex-snapshot
Predicting continuous amyloid PET levels with CSF and plasma brain‐derived p‐tau217
inferred← citeshttps://doi.org/10.1002/alz.71763openalex-snapshot
Optimized plasma p‐tau217 and p‐tau217/Aβ42 cutoffs enhance detection of pre‐clinical Alzheimer's disease across diverse participants
inferred← citeshttps://doi.org/10.1002/alz.71768openalex-snapshot
Interpreting p‐tau217 on the ward: frailty and plasma biomarkers in acutely admitted older adults
inferred← citeshttps://doi.org/10.1002/alz.71828openalex-snapshot
Cerebral oxygen extraction fraction as a physiological biomarker in vascular cognitive impairment: A study in older adults enriched for small vessel diseases
inferred← citeshttps://doi.org/10.1002/ana.26620openalex-snapshot
Change in Cerebrospinal Fluid Tau Microtubule Binding Region Detects Symptom Onset, Cognitive Decline, Tangles, and Atrophy in Dominantly Inherited Alzheimer's Disease
inferred← citeshttps://doi.org/10.1002/ana.27008openalex-snapshot
Head‐to‐Head Comparison of Tau and Amyloid Positron Emission Tomography Visual Reads for Differential Diagnosis of Neurodegenerative Disorders: An International, Multicenter Study
inferred← citeshttps://doi.org/10.1002/ana.27285openalex-snapshot
Timing of Changes in Alzheimer's Disease Plasma Biomarkers as Assessed by Amyloid and Tau PET Clocks
inferred← citeshttps://doi.org/10.1002/ana.78003openalex-snapshot
Predictive Value of Plasma Biomarkers in Tau‐ PET Transitions
inferred← citeshttps://doi.org/10.1002/ana.78109openalex-snapshot
Serum p‐tau217 Is a Prognostic Indicator of Cognitive Impairment in Idiopathic REM Sleep Behavior Disorder
inferred← citeshttps://doi.org/10.1002/ana.78322openalex-snapshot
Cross‐Sectional and Longitudinal Diagnostic Performance of Plasma p‐tau217 and p‐tau217/Aβ42 in Alzheimer's Disease
inferred← citeshttps://doi.org/10.1002/anse.70092openalex-snapshot
Biosensors for Alzheimer's Disease Detection and Monitoring: Bridging Preclinical and Clinical Applications
inferred← citeshttps://doi.org/10.1002/bab.70083openalex-snapshot
Analysis of Single Particles of Amyloid Beta and α‐Synuclein With Seeded Amplification for the Diagnosis of Alzheimer's and Parkinson's Disease
inferred← citeshttps://doi.org/10.1002/dad2.12465openalex-snapshot
Harmonization and standardization of biofluid‐based biomarker measurements for AT(N) classification in Alzheimer's disease
inferred← citeshttps://doi.org/10.1002/dad2.12487openalex-snapshot
Relationship between baseline plasma p‐tau181 and longitudinal changes in cognition and structural brain measures in a cohort of cognitively unimpaired older adults
inferred← citeshttps://doi.org/10.1002/dad2.12496openalex-snapshot
Association of plasma biomarkers with cognitive function in persons with dementia and cognitively healthy in the Democratic Republic of Congo
inferred← citeshttps://doi.org/10.1002/dad2.12514openalex-snapshot
Plasma p‐tau217, p‐tau181, and NfL as early indicators of dementia risk in a community cohort: The Shanghai Aging Study
inferred← citeshttps://doi.org/10.1002/dad2.12545openalex-snapshot
Performance of the Lumipulse plasma Aβ42/40 and pTau181 immunoassays in the detection of amyloid pathology
inferred← citeshttps://doi.org/10.1002/dad2.12617openalex-snapshot
Plasma p‐tau217 concordance with amyloid PET among ethnically diverse older adults
inferred← citeshttps://doi.org/10.1002/dad2.70003openalex-snapshot
Performance of plasma p‐tau217 and NfL in an unselected memory clinic setting
inferred← citeshttps://doi.org/10.1002/dad2.70068openalex-snapshot
Blood phosphorylated Tau181 reliably differentiates amyloid‐positive from amyloid‐negative subjects in the Alzheimer's disease continuum: A systematic review and meta‐analysis
inferred← citeshttps://doi.org/10.1002/dad2.70071openalex-snapshot
Serum biomarkers as prognostic markers for Alzheimer's disease in a clinical setting
inferred← citeshttps://doi.org/10.1002/dad2.70080openalex-snapshot
Clinical performance of the fully automated Lumipulse plasma p‐tau217 assay in mild cognitive impairment and mild dementia
inferred← citeshttps://doi.org/10.1002/dad2.70116openalex-snapshot
The two cut‐offs approach for plasma p‐tau217 in detecting Alzheimer's disease in subjective cognitive decline and mild cognitive impairment
inferred← citeshttps://doi.org/10.1002/dad2.70139openalex-snapshot
Clinical validation of the Lilly SP‐X P‐tau217 assay: Performance in underrepresented cohorts
inferred← citeshttps://doi.org/10.1002/dad2.70164openalex-snapshot
Racial and ethnic differences in plasma p‐tau217 ratio biomarker eligibility rates in a preclinical AD trial with lecanemab
inferred← citeshttps://doi.org/10.1002/dad2.70179openalex-snapshot
Preclinical dementia rating scores are associated with plasma phosphorylated tau‐217
inferred← citeshttps://doi.org/10.1002/dad2.70194openalex-snapshot
Establishment and verification of reference intervals for Alzheimer's disease plasma biomarkers based on evaluation of pre‐analytical procedures: a multicenter study
inferred← citeshttps://doi.org/10.1002/dad2.70201openalex-snapshot
P‐tau217 testing impact on intended management of patients presenting with cognitive impairment: A randomized clinical utility study
inferred← citeshttps://doi.org/10.1002/dad2.70237openalex-snapshot
Motor, not cognitive, performance relates to amyloid status in normal older adults
inferred← citeshttps://doi.org/10.1002/dad2.70420openalex-snapshot
Comparison of a multi‐analyte algorithmic immunoassay blood test with immunoprecipitation mass spectrometry for the detection of amyloid pathology
inferred← citeshttps://doi.org/10.1002/dad2.70439openalex-snapshot
Elecsys pT181p immunoassay: Clinical performance for ruling out amyloid pathology
inferred← citeshttps://doi.org/10.1002/gps.70138openalex-snapshot
Associations of Plasma p‐tau181 With Age, Adjusted for Kidney Function and Sociodemographic Factors
inferred← citeshttps://doi.org/10.1002/mds.30238openalex-snapshot
Plasma Phosphorylated Tau181 as a Biomarker for Alzheimer's Disease Co‐Pathology in Lewy Body Disease
inferred← citeshttps://doi.org/10.1002/mds.70392openalex-snapshot
Plasma p‐tau217 Versus p‐tau181 in Parkinson's Disease: Differential Associations with Alzheimer's Disease‐Related Neurostructural Changes and Cognitive Function
inferred← citeshttps://doi.org/10.1002/nep3.58openalex-snapshot
Blood‐based biomarkers of Alzheimer's disease: Standardization and comprehensiveness
inferred← citeshttps://doi.org/10.1002/orm2.70032openalex-snapshot
Progress in Defining Blood Biomarkers for Alzheimer's Disease Based on Biochemical Mass Spectrometry Platforms
inferred← citeshttps://doi.org/10.1002/trc2.12456openalex-snapshot
Increasing the sensitivity of Simoa via bead count reduction facilitates the quantification of pTau‐181 in dried plasma spots
inferred← citeshttps://doi.org/10.1002/trc2.70013openalex-snapshot
Application of the revised criteria for diagnosis and staging of Alzheimer's disease: Drug development and clinical practice
inferred← citeshttps://doi.org/10.1002/trc2.70050openalex-snapshot
The Common Alzheimer's Disease Research Ontology (CADRO) for biomarker categorization
inferred← citeshttps://doi.org/10.1002/viw.20240119openalex-snapshot
Advances in blood‐based phosphorylated tau protein biomarkers and their detection technology for Alzheimer's disease
inferred← citeshttps://doi.org/10.1007/978-1-0716-3195-9_25openalex-snapshot
Machine Learning for Alzheimer’s Disease and Related Dementias
inferred← citeshttps://doi.org/10.1007/978-3-031-68237-7_44openalex-snapshot
Biomarkers for Neurodegenerative Diseases
inferred← citeshttps://doi.org/10.1007/978-3-031-80849-4_1openalex-snapshot
Fluid and Imaging Markers of Amyloid Pathology
inferred← citeshttps://doi.org/10.1007/978-3-031-80849-4_20openalex-snapshot
Imaging Markers of Amyloid and Tau in Alzheimer Disease
inferred← citeshttps://doi.org/10.1007/978-981-95-5222-1_1openalex-snapshot
The Dementia Cascade: From the Preclinical Stage
inferred← citeshttps://doi.org/10.1007/s00018-025-05668-yopenalex-snapshot
An update on mammalian and non-mammalian animal models for biomarker development in neurodegenerative disorders
inferred← citeshttps://doi.org/10.1007/s00115-023-01544-xopenalex-snapshot
Therapie – Quo vadis Neurodegeneration?
inferred← citeshttps://doi.org/10.1007/s00259-025-07452-3openalex-snapshot
Comparison of two preprocessing methods for 18F-Flortaucipir PET quantification in Alzheimer’s disease
inferred← citeshttps://doi.org/10.1007/s00259-025-07457-yopenalex-snapshot
Potential utility of plasma pTau217 for assessing amyloid and tau biomarker profiles
inferred← citeshttps://doi.org/10.1007/s00401-023-02594-wopenalex-snapshot
Plasma biomarkers for prediction of Alzheimer’s disease neuropathologic change
inferred← citeshttps://doi.org/10.1007/s00401-023-02660-3openalex-snapshot
Optimal blood tau species for the detection of Alzheimer’s disease neuropathology: an immunoprecipitation mass spectrometry and autopsy study
inferred← citeshttps://doi.org/10.1007/s00401-025-02881-8openalex-snapshot
The interactome of tau phosphorylated at T217 in Alzheimer’s disease human brain tissue
inferred← citeshttps://doi.org/10.1007/s00401-025-02888-1openalex-snapshot
Annexin A6 membrane repair protein protects against amyloid-induced dystrophic neurites and tau phosphorylation in Alzheimer’s disease model mice
inferred← citeshttps://doi.org/10.1007/s00401-025-02966-4openalex-snapshot
Confirmation of p-tau Ser356’s association with Alzheimer’s disease pathology and lowering in response to WZ4003 treatment in brain slice cultures. Reply to: “Phospho-tau Ser356 is mostly confined to pre-NFT neurons in Alzheimer’s pathology”
inferred← citeshttps://doi.org/10.1007/s00406-025-02013-zopenalex-snapshot
Plasma biomarkers of amyloid, tau & neuroinflammation in Alzheimer’s disease and corticobasal syndrome
inferred← citeshttps://doi.org/10.1007/s00406-025-02123-8openalex-snapshot
Evaluation of a fully automated assay for the measurement of plasma pTau217 and a composite score integrating the ratio Aβ1-42/1-40 as biomarkers of Alzheimer’s disease
inferred← citeshttps://doi.org/10.1007/s00406-026-02353-4openalex-snapshot
Diagnostic value of blood p-tau subtypes in Alzheimer’s disease progression and pathology: systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1007/s00415-023-12148-5openalex-snapshot
Head-to-head study of diagnostic accuracy of plasma and cerebrospinal fluid p-tau217 versus p-tau181 and p-tau231 in a memory clinic cohort
inferred← citeshttps://doi.org/10.1007/s00415-024-12631-7openalex-snapshot
Diagnostic accuracy of automated Lumipulse plasma pTau-217 in Alzheimer’s disease: a real-world study
inferred← citeshttps://doi.org/10.1007/s00415-025-12996-3openalex-snapshot
Blood phosphorylated Tau217 distinguishes amyloid-positive from amyloid-negative subjects in the Alzheimer's disease continuum. A systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1007/s00415-025-13556-5openalex-snapshot
Plasma p-Tau217 and GFAP predict widespread cognitive decline in Alzheimer’s disease
inferred← citeshttps://doi.org/10.1007/s00415-026-13651-1openalex-snapshot
Salivary total tau: a clinically practical measure of tau neuropathology in Alzheimer’s disease
inferred← citeshttps://doi.org/10.1007/s00415-026-13726-zopenalex-snapshot
Plasma p-tau217 assays effectively predict amyloid status but lack precision for tau staging in Alzheimer’s disease
inferred← citeshttps://doi.org/10.1007/s00415-026-13996-7openalex-snapshot
Blood-based multimodal biomarker models for differentiating early-onset Alzheimer’s disease from frontotemporal dementia: a longitudinal study of early-onset dementia and family members (LEAF) study
inferred← citeshttps://doi.org/10.1007/s10072-023-07258-xopenalex-snapshot
Is blood pTau a reliable indicator of the CSF status? A narrative review
inferred← citeshttps://doi.org/10.1007/s10072-026-08931-7openalex-snapshot
Blood-based biomarkers for Alzheimer’s disease diagnosis: a joint position paper from the Italian Societies of Neurology (SIN) and of Clinical Biochemistry and Clinical Molecular Biology - Laboratory Medicine(SIBioC) and from the Autonomous Association affiliated with SIN for dementia (SINdem)
inferred← citeshttps://doi.org/10.1007/s10571-026-01752-4openalex-snapshot
Plasma Biomarkers for Alzheimer’s Disease Across the Continuum: A Systematic Review of SIMOA-Based Studies
inferred← citeshttps://doi.org/10.1007/s11357-026-02560-wopenalex-snapshot
Motor speech markers of Alzheimer’s risk
inferred← citeshttps://doi.org/10.1007/s12035-025-05219-3openalex-snapshot
The Role of Glial Fibrillary Acidic Protein in the Neuropathology of Alzheimer’s Disease and Its Potential as a Blood Biomarker for Early Diagnosis and Progression
inferred← citeshttps://doi.org/10.1007/s40120-024-00658-xopenalex-snapshot
Navigating the Landscape of Plasma Biomarkers in Alzheimer's Disease: Focus on Past, Present, and Future Clinical Applications
inferred← citeshttps://doi.org/10.1007/s40273-024-01443-2openalex-snapshot
Costs of Care in Relation to Alzheimer’s Disease Severity in Sweden: A National Registry-Based Cohort Study
inferred← citeshttps://doi.org/10.1007/s40291-025-00789-3openalex-snapshot
Current Methods in Clinical Alzheimer’s Disease Research and Diagnosis
inferred← citeshttps://doi.org/10.1007/s40520-026-03420-5openalex-snapshot
Head-to-head comparison of neurodegeneration biomarkers across two analytical platforms in Alzheimer’s disease
inferred← citeshttps://doi.org/10.1007/s41999-023-00847-1openalex-snapshot
The emerging role of blood biomarkers in diagnosis and treatment of Alzheimer’s disease
inferred← citeshttps://doi.org/10.1007/s42399-026-02299-7openalex-snapshot
Neuroimaging Modalities in Alzheimer’s Brain: An Integrative Review of Advanced Neurovisualization Techniques, Emerging Biomarkers, and Translational Strategies for Early Diagnosis and Disease Progression Monitoring
inferred← citeshttps://doi.org/10.1016/b978-0-443-15540-6.00004-5openalex-snapshot
Current status of prevention strategies adapted for Alzheimer's disease
inferred← citeshttps://doi.org/10.1016/b978-0-443-19129-9.00005-4openalex-snapshot
Biosensors for detection of Alzheimer’s disease: a review
inferred← citeshttps://doi.org/10.1016/b978-0-443-28979-8.00001-2openalex-snapshot
Biomarkers for presymptomatic diagnosis and prognosis
inferred← citeshttps://doi.org/10.1016/b978-0-443-30008-0.00004-1openalex-snapshot
Neurocognitive assessment in Alzheimer's disease clinical research
inferred← citeshttps://doi.org/10.1016/bs.acc.2026.09.001openalex-snapshot
Single-molecule protein sequencing: One step closer to the ultimate performance of protein biomarker assays
inferred← citeshttps://doi.org/10.1016/bs.irn.2026.01.002openalex-snapshot
Blood-based emerging biomarkers in early detection and diagnosis of Alzheimer’s disease
inferred← citeshttps://doi.org/10.1016/j.amepre.2024.11.019openalex-snapshot
Test for Comparing the Associations of Multiple Exposures With a Common Outcome
inferred← citeshttps://doi.org/10.1016/j.arr.2024.102257openalex-snapshot
Circulating biomarkers of inflammaging and Alzheimer’s disease to track age-related trajectories of dementia: Can we develop a clinically relevant composite combination?
inferred← citeshttps://doi.org/10.1016/j.arr.2024.102290openalex-snapshot
A critical appraisal of blood-based biomarkers for Alzheimer’s disease
inferred← citeshttps://doi.org/10.1016/j.arr.2024.102599openalex-snapshot
An overview of the genes and biomarkers in Alzheimer’s disease
inferred← citeshttps://doi.org/10.1016/j.arr.2026.103097openalex-snapshot
Tau phosphorylation homeostasis: Mechanisms, targets, and therapeutic implications in Alzheimer’s disease
inferred← citeshttps://doi.org/10.1016/j.arr.2026.103366openalex-snapshot
Sociodemographic and clinical characteristics of participants in blood p-tau217 studies for Alzheimer’s disease: A systematic review
inferred← citeshttps://doi.org/10.1016/j.bbih.2024.100834openalex-snapshot
Synergistic effects of GFAP and Aβ42: Implications for white matter integrity and verbal memory across the cognitive spectrum
inferred← citeshttps://doi.org/10.1016/j.brainres.2024.148812openalex-snapshot
Present and Future of Blood-Based Biomarkers of Alzheimer’s Disease: Beyond the Classics
inferred← citeshttps://doi.org/10.1016/j.brainres.2025.150138openalex-snapshot
Advances in plasma biomarkers for the diagnosis of Alzheimer’s disease
inferred← citeshttps://doi.org/10.1016/j.cca.2026.121255openalex-snapshot
An accessible digital single-molecule sensing platform for plasma P-tau217 quantification in Alzheimer's disease screening
inferred← citeshttps://doi.org/10.1016/j.cell.2026.06.006openalex-snapshot
Recent advances in Alzheimer’s disease: From molecular mechanisms to therapeutic strategies
inferred← citeshttps://doi.org/10.1016/j.clinbiochem.2025.110980openalex-snapshot
The biological diagnosis of Alzheimer’s disease using blood-based biomarkers: A Canadian prospective
inferred← citeshttps://doi.org/10.1016/j.clinbiochem.2025.111015openalex-snapshot
The biological diagnosis of Alzheimer’s disease using blood-based biomarkers: a Canadian prospective
inferred← citeshttps://doi.org/10.1016/j.ebiom.2023.104547openalex-snapshot
Plasma and cerebrospinal fluid glial fibrillary acidic protein levels in adults with Down syndrome: a longitudinal cohort study
inferred← citeshttps://doi.org/10.1016/j.ebiom.2024.105046openalex-snapshot
Comparison of two plasma p-tau217 assays to detect and monitor Alzheimer’s pathology
inferred← citeshttps://doi.org/10.1016/j.ebiom.2024.105345openalex-snapshot
Clinical value of plasma pTau181 to predict Alzheimer's disease pathology in a large real-world cohort of a memory clinic
inferred← citeshttps://doi.org/10.1016/j.ebiom.2024.105405openalex-snapshot
Detection and staging of Alzheimer's disease by plasma pTau217 on a high throughput immunoassay platform
inferred← citeshttps://doi.org/10.1016/j.ebiom.2024.105504openalex-snapshot
Disentangling relationships between Alzheimer's disease plasma biomarkers and established biomarkers in patients of tertiary memory clinics
inferred← citeshttps://doi.org/10.1016/j.ebiom.2025.105659openalex-snapshot
Exploring the neuromagnetic signatures of cognitive decline from mild cognitive impairment to Alzheimer's disease dementia
inferred← citeshttps://doi.org/10.1016/j.ebiom.2025.105741openalex-snapshot
A plasma biomarker panel for detecting early amyloid-β accumulation and its changes in middle-aged cognitively unimpaired individuals at risk for Alzheimer’s disease
inferred← citeshttps://doi.org/10.1016/j.ebiom.2025.105805openalex-snapshot
Comparative performance of plasma pTau181/Aβ42, pTau217/Aβ42 ratios, and individual measurements in detecting brain amyloidosis
inferred← citeshttps://doi.org/10.1016/j.eclinm.2023.102276openalex-snapshot
A neuroimaging biomarker for Individual Brain-Related Abnormalities In Neurodegeneration (IBRAIN): a cross-sectional study
inferred← citeshttps://doi.org/10.1016/j.isci.2023.108534openalex-snapshot
Cell-free RNA signatures predict Alzheimer’s disease
inferred← citeshttps://doi.org/10.1016/j.jagp.2024.09.015openalex-snapshot
Where Do Plasma Biomarkers fit in With Current Alzheimer's Disease Detection?
inferred← citeshttps://doi.org/10.1016/j.jci.2026.100008openalex-snapshot
Beyond amyloid and tau: Emerging pathogenic mechanisms, biomarkers, and therapeutic prospects of Alzheimer's disease
inferred← citeshttps://doi.org/10.1016/j.jfma.2024.01.018openalex-snapshot
Application of blood-based biomarkers of Alzheimer's disease in clinical practice: Recommendations from Taiwan Dementia Society
inferred← citeshttps://doi.org/10.1016/j.jprot.2026.105698openalex-snapshot
From prediction to mechanism: Explainable AI uncovers plasma and CSF proteomic signatures of Alzheimer's disease
inferred← citeshttps://doi.org/10.1016/j.lanepe.2024.101077openalex-snapshot
Blood-based biomarkers in the oldest old: towards Alzheimer's disease detection in primary care
inferred← citeshttps://doi.org/10.1016/j.lanhl.2024.07.013openalex-snapshot
Challenges in the practical implementation of blood biomarkers for Alzheimer’s disease
inferred← citeshttps://doi.org/10.1016/j.lanhl.2025.100717openalex-snapshot
Factors related to blood-based biomarkers for neurodegenerative diseases and their intergenerational associations in the Young Finns Study: a cohort study
showing the first 200 of 511 · page through all 511
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.